Terms: = Breast cancer AND HMGA1, MGC4242, 3159, ENSG00000137309, MGC12816, HMGIY, P17096, MGC4854, HMG-R AND Treatment
19 results:
1. Targeting hmga1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT.
Chang X; Liu J; Yang Q; Gao Y; Ding X; Zhao J; Li Y; Liu Z; Li Z; Wu Y; Zuo D
Biochem Pharmacol; 2023 Jun; 212():115582. PubMed ID: 37146833
[TBL] [Abstract] [Full Text] [Related]
2. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven breast cancer.
Gou X; Kim BJ; Anurag M; Lei JT; Young MN; Holt MV; Fandino D; Vollert CT; Singh P; Alzubi MA; Malovannaya A; Dobrolecki LE; Lewis MT; Li S; Foulds CE; Ellis MJ
Cancer Res; 2023 Oct; 83(19):3237-3251. PubMed ID: 37071495
[TBL] [Abstract] [Full Text] [Related]
3. Copy Number Variation in Inflammatory breast cancer.
Hazra A; O'Hara A; Polyak K; Nakhlis F; Harrison BT; Giordano A; Overmoyer B; Lynce F
Cells; 2023 Apr; 12(7):. PubMed ID: 37048158
[TBL] [Abstract] [Full Text] [Related]
4. Exosomal delivery of 7SK long non-coding RNA suppresses viability, proliferation, aggressiveness and tumorigenicity in triple negative breast cancer cells.
Farhadi S; Mohammadi-Yeganeh S; Kiani J; Hashemi SM; Koochaki A; Sharifi K; Ghanbarian H
Life Sci; 2023 Jun; 322():121646. PubMed ID: 37011870
[TBL] [Abstract] [Full Text] [Related]
5. hmga1 Regulates the Expression of Replication-Dependent Histone Genes and Cell-Cycle in breast cancer Cells.
Petrosino S; Pacor S; Pegoraro S; Gazziero VA; Canarutto G; Piazza S; Manfioletti G; Sgarra R
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614035
[TBL] [Abstract] [Full Text] [Related]
6. Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
Su Y; Dang NM; Depypere H; Santucci-Pereira J; Gutiérrez-Díez PJ; Kanefsky J; Janssens JP; Russo J
Eur J Cancer Prev; 2023 Mar; 32(2):126-138. PubMed ID: 35881946
[TBL] [Abstract] [Full Text] [Related]
7. The synergy between miR-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant breast cancer cells.
Mansoori B; Najafi S; Mohammadi A; AsadollahSeraj H; Savadi P; Mansoori B; Nazari A; Mokhtarzadeh A; Roshani E; Duijf PH; Cho WC; Baradaran B
Biomed Pharmacother; 2021 Sep; 141():111925. PubMed ID: 34323695
[TBL] [Abstract] [Full Text] [Related]
8. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic breast cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Implications of Extracellular hmga1 in breast cancer.
Méndez O; Pérez J; Soberino J; Racca F; Cortés J; Villanueva J
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779212
[TBL] [Abstract] [Full Text] [Related]
11. Extracellular hmga1 Promotes Tumor Invasion and Metastasis in Triple-Negative breast cancer.
Méndez O; Peg V; Salvans C; Pujals M; Fernández Y; Abasolo I; Pérez J; Matres A; Valeri M; Gregori J; Villarreal L; Schwartz S; Ramon Y Cajal S; Tabernero J; Cortés J; Arribas J; Villanueva J
Clin Cancer Res; 2018 Dec; 24(24):6367-6382. PubMed ID: 30135148
[TBL] [Abstract] [Full Text] [Related]
12. Aberrant Expression of miR-142-3p and its Target Gene hmga1 and FZD7 in breast cancer and its Clinical Significance.
Jia XP; Meng LL; Fang JC; Wang HW; Chen J; Zhou J; Wang CN; Jiang WF
Clin Lab; 2018 Jun; 64(6):915-921. PubMed ID: 29945308
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer.
Zhao XX; Yuan QZ; Mu DP; Sun DW; Bo QA; Pan GZ; Li GQ; Cui T; Ding PP; You FP; Hao L; Wang MX; Zhang J
Int J Clin Exp Pathol; 2015; 8(1):368-73. PubMed ID: 25755724
[TBL] [Abstract] [Full Text] [Related]
14. TGF-β1 induces hmga1 expression in human breast cancer cells: implications of the involvement of hmga1 in TGF-β signaling.
Zu X; Zhong J; Tan J; Tan L; Yang D; Zhang Q; Ding W; Liu W; Wen G; Liu J; Cao R; Jiang Y
Int J Mol Med; 2015 Mar; 35(3):693-701. PubMed ID: 25572132
[TBL] [Abstract] [Full Text] [Related]
15. Knockdown of hmga1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice.
Di Cello F; Shin J; Harbom K; Brayton C
Biochem Biophys Res Commun; 2013 Apr; 434(1):70-4. PubMed ID: 23545254
[TBL] [Abstract] [Full Text] [Related]
16. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract] [Full Text] [Related]
17. Negative regulation of BRCA1 gene expression by hmga1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.
Baldassarre G; Battista S; Belletti B; Thakur S; Pentimalli F; Trapasso F; Fedele M; Pierantoni G; Croce CM; Fusco A
Mol Cell Biol; 2003 Apr; 23(7):2225-38. PubMed ID: 12640109
[TBL] [Abstract] [Full Text] [Related]
18. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias.
Scala S; Portella G; Fedele M; Chiappetta G; Fusco A
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4256-61. PubMed ID: 10759549
[TBL] [Abstract] [Full Text] [Related]
19. Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines.
Holth LT; Thorlacius AE; Reeves R
DNA Cell Biol; 1997 Nov; 16(11):1299-309. PubMed ID: 9407002
[TBL] [Abstract] [Full Text] [Related]
